Intuitive Surgical stock slips 2.37% after earlier report
Published on 11/05/2026 at 17:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth Meets Legal Overhang
- Third-quarter revenue rose 22 percent, supported by procedure growth and higher system placements.
- A proposed antitrust settlement reduced GAAP earnings, while non-GAAP profit increased year over year.
- Management kept its 2026 da Vinci procedure outlook near the midpoint of its 14 percent to 15 percent range.
Intuitive Surgical reported strong operating growth for the quarter ended September 30, 2026, while a proposed antitrust settlement weighed on reported earnings. The company disclosed the results and legal agreement on October 20 in a SEC filing.
What changed since the last report
Intuitive Surgical stock traded at 420.53 euros on Lang & Schwarz at 17:05 CET on Thursday, November 5, 2026. The quote was 2.37 percent below the 430.75 euro level recorded at 14:32 CET in the earlier report published the same day. This report-to-report comparison is separate from a daily Xetra comparison.
The company generated third-quarter revenue of 3.05 billion US dollars, up 22 percent from the prior-year period. Worldwide procedures across the da Vinci and Ion platforms grew approximately 15 percent, including approximately 14 percent growth for da Vinci and approximately 31 percent for Ion.
Legal charge splits the earnings picture
GAAP net income attributable to Intuitive Surgical fell to 523 million US dollars, or 1.49 US dollars per diluted share, from 704 million US dollars, or 1.95 US dollars, a year earlier. The result included a 450 million US-dollar pre-tax charge related to a proposed settlement of previously disclosed antitrust class-action litigation.
The agreement provides for a one-time payment and mutually agreed injunctive relief without an admission of liability or wrongdoing. It remains subject to preliminary and final court approval. On a non-GAAP basis, net income rose to 1.05 billion US dollars from 867 million US dollars, while diluted earnings increased to 3.00 US dollars from 2.40 US dollars.
Procedure outlook remains central
Intuitive placed 546 da Vinci systems during the quarter, including 315 da Vinci 5 systems, and expanded its da Vinci installed base to 12,094 systems at September 30. Management kept its full-year 2026 outlook for worldwide da Vinci procedure growth of approximately 14 percent to 15 percent, with growth expected near the midpoint.
Investors will weigh the durability of procedure growth and system adoption against legal costs, tariffs and spending needed to support expansion. The company also projects a non-GAAP gross margin of 68.7 percent to 69.3 percent and operating expense growth of 11 percent to 13 percent for 2026.
Follow the real-time quote of Intuitive Surgical stock for the latest trading level.
Broader market sentiment remains relevant for high-growth healthcare technology shares; see the S&P 500 market coverage.
See more news and analyses on Intuitive Surgical stock.
Intuitive Surgical, Inc. at a glance
- Company: Intuitive Surgical, Inc.
- ISIN: US46120E6023
- Ticker: ISRG
- Home exchange: Nasdaq Global Select Market
- Lang & Schwarz price: 420.53 euros at 17:05 CET on November 5, 2026
- Third-quarter revenue: 3.05 billion US dollars for the quarter ended September 30, 2026
- 2026 procedure outlook: 14 percent to 15 percent da Vinci growth
